ANATOMICAL DISPOSITION OF CARPAL BONES OF GOLDEN RETRIEVER DOG BY X-RAY EXPOSURE

The present study was conducted to know the general disposition of bones in carpal region of experimental dogs by X-ray study with an objective that the findings will facilitate to have an in-depth knowledge about the proper positioning of the carpal bones for surgical management of fractures and different types of bone deformities in dogs. In the present study, the anatomical disposition and arrangement pattern of carpal bones playing a pivotal role in providing the structural conformity in the limbs of Golden Retriever dog has been thoroughly confirmed by Xray exposure

Particle density fluctuations

Event-by-event fluctuations in the multiplicities of charged particles and photons at SPS energies are discussed. Fluctuations are studied by controlling the centrality of the reaction and rapidity acceptance of the detectors. Results are also presented on the event-by-event study of correlations between the multiplicity of charged particles and photons to search for DCC-like signals.Comment: Talk presented at Quark Matter 2002, Nantes, Franc

Tick-borne ehrlichiosis infection in human beings

Human monocytic ehrlichiosis is a tick-borne infectious disease transmitted by several tick species, especially Amblyomma spp caused by Ehrlichia chaffeensis. E. chaffeensis is an obligatory intracellular, tick-transmitted bacterium that is maintained in nature in a cycle involving at least one and perhaps several vertebrate reservoir hosts. Two additional Ehrlichia spp, Anaplasma (formerly Ehrlichia) phagocytophila (the agent of human granulocytic ehrlichiosis [HGE]) and E. ewingii (a cause of granulocytic ehrlichiosis in dogs) act as human pathogens. Human E. chaffeensis infections have generally been reported in North America, Asia and Europe, but recently human cases have been reported in Brazil only. Human monocytic ehrlichiosis is diagnosed by demonstration of a four-fold or greater change in antibody titer to E. chaffeensis antigen by IFA in paired serum samples, or a positive PCR assay and confirmation of E. chaffeensis DNA, or identification of morulae in leukocytes and a positive IFA titer to E. chaffeensis antigen, or immunostaining of E. chaffeensis antigen in a biopsy or autopsy sample, or culture of E. chaffeensis from a clinical specimen

Recombinant Protein and DNA Vaccine Construct of Brucella abortus L7/L12 Gene Elicits Immune Response

Both cell mediated and humoral immune responses are required for recovery from Brucella abortus infection. In the development of vaccines capable of providing immunity against brucellosis, L7/L12 50S ribosomal protein has been demonstrated to be one of the protective immunogens of Brucella abortus. The recombinant Brucella abortus L7/L12 ribosomal protein previously produced in the E. coli system was purified by affinity chromatography. The DNA vaccine (pVL7/L12) construct was purified in bulk by endotoxin free reagents. The present study was designed to evaluate cell mediated immune response and humoral immune response after the intramuscular vaccination of mice with DNA vaccine alone (Group 1), recombinant protein alone (Group 2) and DNA vaccine followed by recombinant protein boosting (Group 3). The protective efficacy of the said vaccines also evaluated. Animals vaccinated with pVL7/L12 (DNA vaccine) alone did not develop L7/L12 specific antibodies at least until 60 days of vaccination. But recombinant protein induced a strong antibody titer (1:32000) after 60 days of post immunization which exhibited a dominance of immunoglobulin IgG2a over IgG1. L7/L12 DNA vaccine elicited a T-cell proliferation response and also induced the production of IFN-γ. The lymphocyte proliferation and IFN- γ production was significantly higher (P<0.001) in Group 3 than the other groups. Group 3 also induced strong IgG2a response. The DNA vaccine followed by protein boosting induced a strong significant level of protection in mice against challenge with B. abortus 544. The level of protection in Group 3 was significantly higher than the DNA vaccine or recombinant protein alone. Altogether, the data generated in the present study suggested that L7/L12 DNA vaccine followed by recombinant protein boosting is a good candidate for use in future studies of vaccination against brucellosis